Holen Sie sich die Stockscreener-App
8.82
2.65%
-0.24
Handel nachbörslich:
8.91
0.09
+1.02%
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
Trendline Breach Raises Concern for REGENXBIO Inc. Investors2025 Price Action Summary & Safe Capital Growth Tips - sundaytimes.kr
Technical analysis overview for REGENXBIO Inc. stock2025 Winners & Losers & Detailed Earnings Play Strategies - Newser
Detecting price anomalies in REGENXBIO Inc. with AIJuly 2025 Movers & Real-Time Volume Analysis - Newser
Can REGENXBIO Inc. hit a new high this monthJuly 2025 WrapUp & Expert Curated Trade Setup Alerts - Newser
Can REGENXBIO Inc. rally from current levelsJuly 2025 Macro Moves & Advanced Technical Signal Analysis - Newser
REGENXBIO’s SWOT analysis: gene therapy pioneer’s stock faces pivotal year - Investing.com Canada
Is a relief rally coming for REGENXBIO Inc. holdersJuly 2025 Outlook & Technical Pattern Alert System - Newser
When is the best time to exit REGENXBIO Inc.Weekly Trade Recap & High Accuracy Investment Entry Signals - Newser
What makes REGENXBIO Inc. stock price move sharplyMarket Growth Review & Free Weekly Chart Analysis and Trade Guides - thegnnews.com
Will breakout in REGENXBIO Inc. lead to full recoveryJuly 2025 Macro Moves & Verified Entry Point Signals - Newser
Are Options Traders Betting on a Big Move in Regenxbio Stock? - Yahoo Finance
What’s next for REGENXBIO Inc. stock priceFree Market Entry and Exit Point Tips - Newser
Investors Don't See Light At End Of REGENXBIO Inc.'s (NASDAQ:RGNX) Tunnel - simplywall.st
XTX Topco Ltd Reduces Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO (NASDAQ:RGNX) Cut to “Strong Sell” at Wall Street Zen - Defense World
Dystrophin Gene Therapy Market 2025 | $12B Growth, REGENXBIO & - openPR.com
Can REGENXBIO Inc. expand its profit marginsSafe Growth Small Cap Picks - thegnnews.com
Royal Bank Of Canada Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - Defense World
REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital - Defense World
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
These Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Forecasts - Yahoo Finance
REGENXBIO Inc. recovery potential after sell offBuy Entry Confirmation Based on Technical Analysis - Newser
REGENXBIO (NASDAQ:RGNX) Stock Price Passes Below Fifty Day Moving Average on Disappointing Earnings - Defense World
REGENXBIO Reports Q2 2025 Financial Results and Progress - The Globe and Mail
Is REGENXBIO Inc. stock a buy or sellElite Portfolio Components - thegnnews.com
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Regenxbio accelerates RGX-202 pivotal enrollment to October 2025 as topline data targeted for early 2026 - MSN
Raymond James Remains a Buy on RegenXBio (RGNX) - The Globe and Mail
Regenxbio: RBC Capital Maintains Outperform, PT Down to $17 from $21 - AInvest
Regenxbio price target lowered to $17 from $21 at RBC Capital - TipRanks
RBC Capital lowers Regenxbio stock price target to $17 on quarterly results - Investing.com
RBC Capital lowers Regenxbio stock price target to $17 on quarterly results By Investing.com - Investing.com South Africa
Regenxbio's Q2 2025: Key Contradictions on RGX-121 Approval, Manufacturing Plans, and Pivotal Study Design - AInvest
REGENXBIO Inc. (RGNX): Navigating Q2 2025 Challenges with a High-Stakes Gene Therapy Pipeline - AInvest
RBC Cuts Price Target on REGENXBIO to $17 From $21, Keeps Outperform, Speculative Risk - MarketScreener
Regenxbio: Chardan Capital maintains Buy, PT raised to $52 from $52. - AInvest
Transcript : REGENXBIO Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Regenxbio 2025 Q2 Earnings Wider Losses Amid Progress in Gene Therapy Pipeline - AInvest
Regenxbio Inc (RGNX) Q2 2025 Earnings Call Highlights: Strong Financial Position and Strategic ... By GuruFocus - Investing.com Canada
Forecasting REGENXBIO Inc. price range with options dataExit Strategy Guide With Risk Control Plan - Newser
Regenxbio: Q2 Earnings Snapshot - Stamford Advocate
Regenxbio Inc. shares rise 1.27% after-hours following the initiation of a pivotal Phase IIb/III clinical trial for diabetic retinopathy. - AInvest
Regenxbio stock maintains Outperform rating at Raymond James on solid cash runway - Investing.com Nigeria
Earnings call transcript: Regenxbio Q2 2025 misses forecasts, stock dips - Investing.com
Earnings call transcript: Regenxbio Q2 2025 misses forecasts, stock dips By Investing.com - Investing.com Canada
Regenxbio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
XtalPi inks pact with Greg Verdine’s DoveTree; Regenxbio, AbbVie update deal - Endpoints News
Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy - TipRanks
Regenxbio Incphase IIb/III trial to be initiated for diabetic retinopathy - MarketScreener
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights - Placera.se
RegenXBio and AbbVie Amend Collaboration Agreement - TipRanks
Regenxbio Inc earnings missed by $0.44, revenue fell short of estimates - Investing.com South Africa
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):